Matching treatment to pathophysiology in type 2 diabetes

Clinical Therapeutics

Volumn 23, Issue 5, 2001, Pages 646-659

  Gerich, John E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Combination therapy; Glyburide; Insulin resistance; Insulin secretion; Metformin; Type 2 diabetes

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; MEGLITINIDE; METFORMIN; MIGLITOL; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

CLINICAL TRIAL; DIARRHEA; DISEASE CLASSIFICATION; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; MEDICAL INFORMATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT FAILURE;

EID: 0035010337     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80017-5     Document Type: Article

References (65)

1. 1. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care. 2000;23:1278-1283.
2. 2. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
3. 3. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes. 1995;44:1249-1258.
4. 4. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab. 1994;78:809A-809F.
5. 5. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
6. 6. Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: The Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia. 1996; 39:1483-1488.
7. 7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998;352: 837-853.
8. 8. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: A randomized, prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
9. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44:968-983.
10. 10. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Br Med J. 2000;321: 405-412.
11. 11. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99-111.
12. 12. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20;1183-1197.
13. 13. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care. 2000;23(Suppl 1):S20-S23.
14. 14. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-1057.
15. 15. World Health Organization. Diabetes mellitus: Report of a WHO Study Group. Geneva: World Health Organization; 1985. Technical Report Series, No. 727.
16. 16. Gerich JE. The genetic basis of type 2 diabetes mellitus: Impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev. 1998;19:491-503.
17. 17. Fajans SS, Bell GI. Maturity-onset diabetes of the young. A model for genetic studies of diabetes mellitus. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus: A Fundamental and Clinical Text. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000:691-705.
18. 18. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
19. 19. DeFronzo RA. Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetes genes. Diabetes Rev. 1997;5:177-269.
20. 20. Groop LC, Bonadonna RC, DelPrato S, et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest. 1989;84:205-213.
21. 21. Edelman SV. Type II diabetes mellitus. Adv Intern Med. 1998;43:449-500.
22. 22. Mitrakou A, Kelley D, Veneman T, et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes. 1990; 39:1381-1390.
23. 23. Neel JV. Diabetes mellitus: A "thrifty" genotype rendered detrimental by "progress." Am J Hum Genet. 1962;14:353-362.
24. 24. Lev-Ran A. Thrifty genotype: How applicable is it to obesity and type 2 diabetes? Diabetes Rev. 1999;7:1-22.
25. 25. Bonadonna RC, Del Prato S, Bonora E, et al. Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. Diabetes. 1996;45:915-925.
26. 26. Magnusson I, Rothman DL, Katz LD, et al. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest. 1992;90:1323-1327.
27. 27. Meyer C, Stumvoll M, Nadkarni V, et al. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest. 1998;102:619-624.
28. 28. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med. 1992;326:22-29.
29. 29. Polonsky KS, Sturis J, Bell GI. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996; 334:777-783.
30. 30. Polonsky KS. Lilly Lecture 1994. The beta-cell in diabetes: From molecular genetics to clinical research. Diabetes. 1995; 44:705-717.
31. 31. Vaag A, Henriksen JE, Madsbad S, et al. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;95:690-698.
32. 32. UK Prospective Diabetes Study. V. Characteristics of newly presenting type 2 diabetic patients: Estimated insulin sensitivity and islet 4-cell function. Multi-centre study. Diabetic Med. 1988;5:444-448.
33. 33. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med. 1998;128: 165-175.
34. 34. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
35. 35. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2000;23(Suppl 1);S32-S42.
36. 36. Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45:1289-1298.
37. 37. Beck-Nielsen H, Pedersen O, Lindskov HO. Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year. Acta Endocrinol (Copenh). 1979;90:103-112.
38. 38. Glyburide. In: McEvoy GK, ed. AHFS Drug Information 2000. Bethesda, Md: American Society of Health-System Pharmacists; 2000:2850-2856.
39. 39. Gromada J, Dissing S, Kofod H, Frøkjær-Jensen J. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia. 1995;38:1025-1032.
40. 40. Keilson L, Mather S, Walter YH, et al. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000;85:1081-1086.
41. 41. Hu S, Wang S, Fanelli B, et al. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther. 2000; 293:444-452.
42. 42. Landgraf R. Approaches to the management of postprandial hyperglycaemia. Exp Clin Endocrinol Diabetes. 1999;107(Suppl 4):S128-S132.
43. 43. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1991; 73:1294-1301.
44. 44. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in noninsulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550-554.
45. 45. Johnson AB, Webster JM, Sum CF, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metab Clin Exp. 1993;42:1217-1222.
46. 46. Acarbose. In: McEvoy GK, ed. AHFS Drug Information 2000. Bethesda, Md: American Society of Health-System Pharmacists; 2000:2862-2864.
47. 47. Rosiglitazone maleate. In: McEvoy GK, ed. AHFS Drug Information 2000. Bethesda, Md: American Society of Health-System Pharmacists; 2000:2876-2877.
48. 48. Bolli GB, Di Marchi RD, Park GD, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999;42:1151-1167.
49. 49. Kaku K, Matsuda M, Urae A, Irie S, Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. Diabetes Res Clin Pract. 2000;49: 119-126.
50. 50. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142-2148.
51. 51. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999; 281:2005-2012.
52. 52. Black HR. Isolated systolic hypertension in the elderly: Lessons from clinical trials and future directions. J Hypertens. 1999; 17(Suppl 5):S49-S54.
53. 53. Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care. 1998;21:2050-2055.
54. 54. Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: A randomized, placebo-controlled study. Diabetic Med. 1999;16:755-761.
55. 55. Schneider R, Egan J, Houser V. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes. Diabetes. 1999;48(Suppl 1):A106. Abstract.
56. 56. Egan J, Rubin C, Mathisen A. Combination therapy with pioglitazone and metformin in patients with type 2 diabetes. Diabetes. 1999;48(Suppl 1):A117. Abstract.
57. 57. Gavin LA, Barth J, Arnold D, Shaw R. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control. Endocr Pract. 2000;6:305-310.
58. 58. Wright AD, Cull CA, Holman RR, Turner RC. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care. 1998;21:87-92.
59. 59. Erle G, Lovise S, Stocchiero C, et al. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients. Acta Diabetol. 1999;36:61-65.
60. 60. Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care. 1994;17:1100-1109.
61. 1c in first-line treatment of type 2 diabetes. Diabetes. 2000;49(Suppl 1):A107. Abstract.
62. 62. Donovan D, Rosenstock J, Mooradian A, Henry D. Effect of metformin/glyburide tablets on fasting plasma glucose in type 2 diabetes. Diabetes. 2000;49(Suppl 1): A103. Abstract.
63. 1c response. Diabetes. 2000;49 (Suppl 1):A356. Abstract.
64. 64. Davidson J, Schneider S, Garber A, Merten J. Metformin/glyburide is safe and well tolerated as first-line therapy in patients with type 2 diabetes. Diabetes. 2000;49(Suppl 1):A356. Abstract.
65. 65. Garber A, Davidson J, Anderson R, Piper BA. Incidence of reported gastrointestinal and hypoglycemic symptoms with metformin/glyburide tablets as first-line therapy in type 2 diabetes. Diabetes. 2000;49 (Suppl 1):A357. Abstract.